Nimbus Therapeutics LLC (Cambridge, Mass.) raised $65 million in a financing led by existing investor Atlas Venture. Also participating were existing investors SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures and Schrödinger.
Since its founding in 2009, the computational chemistry company has used a business model in which its programs are housed in separate subsidiaries for the express purpose of making them easier to sell off early in the development process. The company’s partners include Celgene Corp. (NASDAQ:CELG) and Gilead Sciences Inc. (NASDAQ:GILD) (see BioCentury Innovations, Oct. 5, 2017).
CEO Donald Nicholson told BioCentury the financing will be used to build the company’s wholly owned pipeline that currently includes about five to six new, undisclosed programs for immunology, oncology and metabolic disease indications.
The funds will give Nimbus two to three years of runway, according to Nicholson. He said the most advanced of its new programs is expected to enter the clinic next year.